Volume: | 367,867 |
Day Range: | 1.73 - 1.835 |
Bid: | 1.79 |
Ask: | 1.80 |
Last Trade Time: | 10:25:17 AM EDT |
Total Trades: | 1,678 |
Recent PRME News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2025 01:16:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2025 01:15:39 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2025 01:21:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2025 01:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2025 01:02:28 PM
- Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 02/28/2025 01:00:00 PM
- Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference • GlobeNewswire Inc. • 02/24/2025 01:00:00 PM
- Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm • PR Newswire (US) • 01/30/2025 05:26:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:01:07 PM
- Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2025 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/23/2024 05:15:19 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/13/2024 01:18:34 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/22/2024 10:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 09:06:21 PM
- Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/12/2024 09:00:00 PM
- Prime Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/06/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 12:04:24 PM
- Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress • GlobeNewswire Inc. • 10/24/2024 12:00:00 PM
- Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings • GlobeNewswire Inc. • 10/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 11:38:53 AM
- Prime Medicine Unveils Strategically Focused Pipeline • GlobeNewswire Inc. • 09/30/2024 11:01:00 AM
- Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies • GlobeNewswire Inc. • 09/30/2024 11:00:00 AM
- Prime Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 12:26:47 PM
Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance • FITY • Mar 14, 2025 10:30 AM
WIN-LIGHT GLOBAL FILES SEC SCHEDULE 13G DISCLOSING 1.96M SHARES OF PASSIVE INSTITUTIONAL INVESTOR OWNERSHIP • CNTM • Mar 14, 2025 7:13 AM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM
$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market • NRXS • Mar 11, 2025 10:30 AM